Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo Inc. (MYO) is a leader in developing wearable medical robotics that restore mobility for individuals with neuromuscular disorders. This page serves as the definitive source for official company announcements, providing stakeholders with timely updates on innovations shaping the orthotics industry.
Access curated press releases covering FDA milestones, product launches, and financial performance reports. Investors will find earnings disclosures and partnership announcements, while healthcare professionals can track clinical trial outcomes and insurance coverage expansions.
Our repository includes updates on Myomo’s myoelectric brace development, research collaborations with medical institutions, and regulatory progress across global markets. All content is sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page to monitor how MYO’s neuro-robotic solutions are advancing patient care while creating long-term value in the medical technology sector. Check regularly for developments impacting both clinical and investment communities.
- Gross margin improved to 67.2%, up 600 basis points - Medicare Part B patients represented 59% of Q1 revenue - Record 700 new candidates added to pipeline, up 42% - Average selling price increased to $54,000, up 31%
Despite positive revenue growth, the company faced challenges with Medicare Advantage plans and social media algorithm changes affecting lead generation. Operating loss narrowed to $3.5 million from $3.9 million year-over-year. The company maintains its full-year 2025 revenue guidance of $50-53 million, projecting 54-63% growth compared to 2024.
Myomo (NYSE American: MYO), a wearable medical robotics company, announces its first-ever Investor & Analyst Day scheduled for June 18, 2025. The event will be held at the company's new corporate headquarters in Burlington, Massachusetts, from 10:00 a.m. to 3:00 p.m. ET. The event will feature presentations from senior management, product demonstrations of the MyoPro® powered arm and hand brace, Q&A sessions, and facility tours. Both in-person and virtual attendance options are available, with the event being webcast live and available for replay. The company will showcase its latest innovations, strategic plans, and growth initiatives in wearable medical robotics for individuals with neuromuscular disorders.
Myomo, a wearable medical robotics company focused on helping patients with neurological disorders and upper-limb paralysis, has scheduled its Q1 2025 financial results announcement for May 7, 2025.
The company will host a conference call at 4:30 p.m. ET, featuring prepared remarks from Paul R. Gudonis, chairman and CEO, and David Henry, CFO. Participants can pre-register for the call through a provided link to receive immediate access via a unique PIN and passcode.
Alternative dial-in options include:
- U.S. callers: 844-707-6932
- International callers: 412-317-9250
A webcast will be available on Myomo's Investor Relations page, with replay access until May 21, 2025. The replay can be accessed via:
- U.S. toll-free: 877-344-7529
- Canada toll-free: 855-669-9658
- International: 412-317-0088
- Access code: 1943669
Myomo has launched the MyoPro 2x, an advanced wearable medical robotics device designed to improve arm and hand function for people with upper-limb paralysis and neuromuscular conditions. The new model features significant improvements in donning, fit, and function, building on experience from over 3,000 previous patients.
Key enhancements include:
- Streamlined and intuitive donning process for consistent fit
- Integration of common customizations into standard design
- Reduced clinician fitting time
- Updated training documentation and instruction guides
Supporting the launch, Myomo has implemented a certification process for Orthotic & Prosthetic providers to become MyoPro Centers of Excellence. This enables certified practices to independently build patient pipelines and dispense the MyoPro 2x. The development process incorporated feedback from users and clinicians, along with Myomo's product performance data.
Myomo (NYSE American: MYO), a wearable medical robotics company specializing in neurological disorders and upper-limb paralysis solutions, announced upcoming board changes. Directors Amy Knapp and Yitzchak Jacobovitz will not seek re-election as Class II directors, with their terms concluding at the 2025 Annual Meeting in June 2025.
Knapp, who joined in July 2016, will continue advising on reimbursement matters, while Jacobovitz, who served since January 2023, will transition to a non-voting board observer role. The company plans to appoint new directors as part of its ongoing governance evolution.
The announcement comes following Myomo's achievement of Medicare Part B coverage for its MyoPro™ device. Both departing directors expressed confidence in the company's strategic direction and its progress toward achieving sustainable positive cash flow.
Myomo (NYSE American: MYO), a wearable medical robotics company focused on neurological disorders and upper-limb paralysis, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
Company executives Paul Gudonis (President and CEO) and David Henry (CFO) will deliver a presentation on Thursday April 10th at 3:00 p.m. ET. The presentation will be available via live webcast and will subsequently be archived in the Investors section of Myomo's website. During the conference, which runs from April 7th to April 10th, the executives will also conduct one-on-one meetings with registered investors.
Myomo (NYSE: MYO) reported record Q4 2024 financial results with revenue reaching $12.1 million, up 154% year-over-year. The company achieved its first-ever positive quarterly cash flow from operations of $3.4 million.
Key highlights include:
- Record 220 MyoPro revenue units, up 106%
- Gross margin improved to 71.4%, up 610 basis points
- 233 new MyoPro authorizations and orders, up 27%
- Pipeline grew to 1,389 candidates, up 33%
- Cash position of $24.9 million as of December 31, 2024
For 2025, Myomo projects revenue between $50-53 million, representing 54-63% growth. Q1 2025 revenue is expected to be $9.0-9.5 million, with the company anticipating return to positive quarterly cash flow from operations by Q4 2025.
Myomo (NYSE American: MYO), a wearable medical robotics company focused on neurological disorders and upper-limb paralysis, has scheduled its fourth quarter and full-year 2024 financial results announcement for March 10, 2025.
The company will host a conference call at 4:30 p.m. ET featuring prepared remarks from Chairman and CEO Paul R. Gudonis and CFO David Henry. Participants can pre-register for the call online or dial in directly using 844-707-6932 (U.S.) or 412-317-9250 (International).
A webcast will be available on Myomo's Investor Relations page, with replay access until March 24, 2025.
Inogen (NASDAQ: INGN) announced changes to its Board of Directors, effective January 2025. Mira Kirti Sahney has been appointed as a new board member, while Tom West will retire after serving since April 2023.
Sahney brings significant medical device industry experience, currently serving on Claria Medical's board and previously as President of Medtronic's Pelvic Health Operating Unit (2021-2024). Her experience includes roles as CEO of Hyalex Orthopaedics, leadership positions at Smith + Nephew, and co-founding Myomo. She holds multiple engineering degrees from University of Michigan and Stanford, plus an MBA from MIT.
In her new role, Sahney will join Inogen's Compliance Committee and the Nominating and Governance Committee. The appointment aims to strengthen Inogen's position as a global leader in respiratory care.
FAQ
What is the current stock price of Myomo (MYO)?
What is the market cap of Myomo (MYO)?
